APARA TECHNOLOGIES
About Us
Apara is a company dedicated to pioneer the future of wound healing and Regenerative Medicine. We believe in developing novel biomaterials that will have applications across various industries like biomedical, tissue engineering and regenerative medicine. Our goals align with UN SDG’s where ewe aim to provide high quality cost effective solutions to not only improve the Quality of patients lives but also reduce the burden on th health care system.
Biomaterials >Tissueink
TissueInk empowers researchers with high-quality, research-grade biomaterials—GELMA, SILMA, Hydroxyapatite, ß Tricalcium Phosphate and more—engineered for reproducibility and innovation in tissue engineering, regenerative medicine, and biomaterials research. Discover our rigorously characterized materials and explore how our portfolio can advance your next breakthrough.
Piezoelectric Biomaterial Composites for Deep Tissue Wound Healing
(Our Deep Research Project)
| ABOUT THE PROJECT
Wound healing is a complex and dynamic process involving sequential but overlapping phases of hemostasis, inflammation, proliferation, and remodeling. Our ultrasound-responsive biopolymer composite will demonstrate multifunctional activity that addresses critical barriers in each of these phases, thereby offering a superior therapeutic strategy for acute as well as chronic wounds. Our product is formulated to ensure that it is cost effective to ensure that it reaches all strata of the society, we are also ensuring that it is biocompatible which is a key factor to ensure that there is no long term toxicity. The BPC Biomaterial closely mimics that of natural adult human skin and will be formulated using two major cells which will be isolated from the wound bed. The Biomechanical Energy from the ultrasound will transform ultrasound signals into electrical cues to trigger bactericidal response, immune polarization, cell proliferation and migration to accelerate the wound healing process within 21 Days.
Our Products & Research Projects
About the Founders..
Piyush Padmanabhan
Piyush is a biotechnology graduate from Vellore Institute of Technology, Vellore and is a seasoned innovation architect, focussed on building and scaling deep tech solutions for a global stage. Dorning multiple hats over the 13+ years of experience, Piyush currently holds three patents in the domain of bioprinting and is one of the top voices in the country with respect to the domain of biofabrication and tissue engineering. While building his first startup, Next Big Innovation Labs®, Piyush spearheaded the efforts to build India’s first customisable bioprinter (Trivima) and has scaled the business from just two Trivima Bioprinter installations in 2021 to over 40 (including local and international) Trivima installations in 2025. He has led key strategic partnerships within Next Big Innovation Labs® such as the partnership with Merck KGaA to build bioprinting solutions for pharmaceutical applications, partnership with Microsoft to build robust AI solutions for Bioprinting (currently in deployment) and pivotal collaboration with institutes such as AIIMS (New Delhi), IIT Madras, IIT Hyderabad and Central Leather Research Institute to expand the applications of bioprinting.
Pooja Venkatesh
Pooja Venkatesh comes from a background of Biotechnology and Mangaement. She has completed her B.E in Biotech from PES University and Masters in Management from Bayes Business School, London.Over the years she has distinguished herself as an innovator and leader, driving major advancements in biotechnology and 3D bioprinting through her work at Next Big Innovation Labs. Among her key accomplishments are securing process patents for bioprinting human tissue, launching India’s first customizable bioprinter (Trivima), and establishing strategic partnerships—including establishing key strategic R&D MoUs and a collaboration with HiMedia Laboratories. Her knowledge on IP and regulatory processes are key in driving translation R&D projects into industry. From helping establish key IP and liasing with different groups within the organization to drive the product readiness for commercialization is Pooja’s key forte. With 9 years of experience in the Biotech Industry and many accomplishments, Pooja helps navigate the IP and regulatory pathways for successful translation and to ensure that the product is ready for commercialization.
Dr. Amit Nain
Dr. Amit Nain is an Assistant Professor at the Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, and the Chief Scientific Officer (CSO) of Apara Technologies. He obtained his B.Tech in Biotechnology from VIT University, Vellore, and a Ph.D. in Nanoscience and Technology from the Department of Engineering & System Science, National Tsing Hua University, Taiwan. His doctoral work focused on developing functional nanomaterials for sensing, antimicrobial therapies, and wound healing, followed by postdoctoral research at National Taiwan University and applied R&D experience at the Taiwan Instrument Research Institute. He further served as a DST INSPIRE Faculty at the Indian Institute of Science, Bengaluru, advancing smart biomaterials and 4D fabrication strategies.
As CSO of Apara Technologies, Dr. Nain sets the long-term scientific vision of the company, aligning it with global advances in biomaterials and tissue engineering. He oversees R&D activities, ensures reproducibility and quality, works closely with regulatory and compliance teams, and collaborates with marketing, sales, and strategy partners to drive product innovation based on design and market requirements. His leadership extends to building academic, clinical, and industrial collaborations, mentoring scientific teams, and representing the company through publications, patents, and international conferences. With over 35 research publications and recognition including the Asian Polymer Association Young Researcher Award (2024) and Emerging Investigator by Journal of Materials Chemistry B (RSC), Dr. Nain combines academic excellence with translational vision to drive innovation in biomaterials and regenerative medicine.